CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13

Summary: Biallelic loss of cyclin-dependent kinase 12 (CDK12) defines a metastatic castration-resistant prostate cancer (mCRPC) subtype. It remains unclear, however, whether CDK12 loss drives prostate cancer (PCa) development or uncovers pharmacologic vulnerabilities. Here, we show Cdk12 ablation in...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Jean Ching-Yi Tien, Jie Luo, Yu Chang, Yuping Zhang, Yunhui Cheng, Xiaoju Wang, Jianzhang Yang, Rahul Mannan, Somnath Mahapatra, Palak Shah, Xiao-Ming Wang, Abigail J. Todd, Sanjana Eyunni, Caleb Cheng, Ryan J. Rebernick, Lanbo Xiao, Yi Bao, James Neiswender, Rachel Brough, Stephen J. Pettitt, Xuhong Cao, Stephanie J. Miner, Licheng Zhou, Yi-Mi Wu, Estefania Labanca, Yuzhuo Wang, Abhijit Parolia, Marcin Cieslik, Dan R. Robinson, Zhen Wang, Felix Y. Feng, Jonathan Chou, Christopher J. Lord, Ke Ding, Arul M. Chinnaiyan
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2024-10-01
Serija:	Cell Reports Medicine
Teme:	CDK12 CDK13 prostate cancer Cdk12 knockout transcription-replication conflicts R-loops
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2666379124004889
Oznake:	Označite Brez oznak, prvi označite!